Performance of the Bethesda System for Reporting Thyroid Cytology in Multi-Institutional Large Cohort of Pediatric Thyroid Nodules: A Detailed Analysis.

Bethesda system FNAC TBSRTC paediatric cytology paediatric thyroid nodules the Bethesda system for reporting thyroid cytology thyroid cytology

Journal

Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402

Informations de publication

Date de publication:
12 Jan 2022
Historique:
received: 02 11 2021
revised: 15 12 2021
accepted: 06 01 2022
entrez: 21 1 2022
pubmed: 22 1 2022
medline: 22 1 2022
Statut: epublish

Résumé

To evaluate the performance of TBSRTC through multi-institutional experience in the paediatric population and questioning the management recommendation of ATA Guidelines Task Force on Paediatric Thyroid Cancer; Methods: A retrospective search was conducted in 4 institutions to identify consecutive thyroid FNAC cases in paediatric population between 2000 and 2018. Following the 2nd TBSRTC, the risk of malignancy ratios (ROMs) was given in ranges and calculated by 2 different ways. Sensitivity, specificity, PPV, NPV and DA ratios were calculated using histologic diagnosis as the gold standard; Results: Among a total of 405 specimens, the distribution of cases for each category was, 44 (11%) for ND, 204 (50%) for B category, 40 (10%) for AUS/FLUS, 36 (9%) for FN/SFN, 24 (6%) for SFM and 57 (14%) for M categories. 153 cases have a histological diagnosis. The ratio of surgery was 23% in ND, 16% in the B, 45% for AUS/FLUS, 75% for SFN/FN and 92% for SFM and 75% in M categories; Conclusions: The data underlines the high ROM values in paediatric population which might be clinically meaningful. The high rate of malignancy of the cohort of operated patients (50%) also underlines the need of better preoperative indicators for stratification. Considering that more than half of the nodules in AUS/FLUS category were benign, direct surgery recommendation could be questionable as proposed in ATA 2015 guidelines.

Sections du résumé

BACKGROUND BACKGROUND
To evaluate the performance of TBSRTC through multi-institutional experience in the paediatric population and questioning the management recommendation of ATA Guidelines Task Force on Paediatric Thyroid Cancer; Methods: A retrospective search was conducted in 4 institutions to identify consecutive thyroid FNAC cases in paediatric population between 2000 and 2018. Following the 2nd TBSRTC, the risk of malignancy ratios (ROMs) was given in ranges and calculated by 2 different ways. Sensitivity, specificity, PPV, NPV and DA ratios were calculated using histologic diagnosis as the gold standard; Results: Among a total of 405 specimens, the distribution of cases for each category was, 44 (11%) for ND, 204 (50%) for B category, 40 (10%) for AUS/FLUS, 36 (9%) for FN/SFN, 24 (6%) for SFM and 57 (14%) for M categories. 153 cases have a histological diagnosis. The ratio of surgery was 23% in ND, 16% in the B, 45% for AUS/FLUS, 75% for SFN/FN and 92% for SFM and 75% in M categories; Conclusions: The data underlines the high ROM values in paediatric population which might be clinically meaningful. The high rate of malignancy of the cohort of operated patients (50%) also underlines the need of better preoperative indicators for stratification. Considering that more than half of the nodules in AUS/FLUS category were benign, direct surgery recommendation could be questionable as proposed in ATA 2015 guidelines.

Identifiants

pubmed: 35054346
pii: diagnostics12010179
doi: 10.3390/diagnostics12010179
pmc: PMC8774335
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Cancer Cytopathol. 2016 Nov;124(11):801-810
pubmed: 27412501
Cancers (Basel). 2021 Sep 18;13(18):
pubmed: 34572919
JAMA Oncol. 2016 Aug 1;2(8):1023-9
pubmed: 27078145
J Pediatr Endocrinol Metab. 2021 Feb 24;34(4):449-455
pubmed: 33629571
Cancers (Basel). 2021 Oct 22;13(21):
pubmed: 34771467
J Pediatr Surg. 2019 Oct;54(10):1969-1975
pubmed: 30902456
Thyroid. 2016 Feb;26(2):219-26
pubmed: 26854950
Thyroid. 2019 Aug;29(8):1097-1104
pubmed: 31298618
Diagn Cytopathol. 2015 Aug;43(8):598-604
pubmed: 25728981
J Clin Endocrinol Metab. 2013 Aug;98(8):3238-45
pubmed: 23737541
J Pediatr Surg. 2015 Jul;50(7):1147-9
pubmed: 25783310
J Pediatr. 2015 Oct;167(4):886-892.e1
pubmed: 26164379
Thyroid. 2015 Jul;25(7):716-59
pubmed: 25900731
Horm Res Paediatr. 2021;94(7-8):263-274
pubmed: 34469888
Cancer Cytopathol. 2012 Oct 25;120(5):342-50
pubmed: 22605559
Genes (Basel). 2019 Sep 18;10(9):
pubmed: 31540418
Ann Intern Med. 2013 Sep 3;159(5):325-32
pubmed: 24026318
Thyroid. 2017 Nov;27(11):1341-1346
pubmed: 29091573
Pediatr Radiol. 2018 Jan;48(1):74-84
pubmed: 28983667
Cancer Cytopathol. 2016 Jul;124(7):467-71
pubmed: 26970342

Auteurs

Sule Canberk (S)

Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal.
Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Rua Júlio Amaral de Carvalho 45, 4200-135 Porto, Portugal.
Abel Salazar Biomedical Sciences Institute (ICBAS), University of Porto, Rua Jorge de Viterbo Ferreira 228, 4050-313 Porto, Portugal.

Helena Barroca (H)

Department of Pathology and Oncology, Centro Hospitalar São João, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal.

Inês Girão (I)

Department of Biomedicine and Medicine, University of Algarve, 8005-139 Faro, Portugal.

Ozlem Aydın (O)

Department of Pathology, Medical Faculty, Acibadem University, Istanbul 34684, Turkey.

Aysun Uguz (A)

Department of Pathology, Medical Faculty, Çukurova University, Adana 01330, Turkey.

Kıvılcım Erdogan (K)

Department of Pathology, Medical Faculty, Çukurova University, Adana 01330, Turkey.

Ebru Tastekin (E)

Department of Pathology, Medical Faculty, Trakya University, Edirne 22030, Turkey.

Massimo Bongiovanni (M)

Synlab Pathology, Rue du Liseron 5, 1006 Lausanne, Switzerland.

Paula Soares (P)

Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal.
Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Rua Júlio Amaral de Carvalho 45, 4200-135 Porto, Portugal.
Department of Pathology, Faculty of Medicine of the University of Porto (FMUP), Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal.

Valdemar Máximo (V)

Instituto de Investigação e Inovação em Saúde (i3S), University of Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal.
Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Rua Júlio Amaral de Carvalho 45, 4200-135 Porto, Portugal.
Department of Pathology, Faculty of Medicine of the University of Porto (FMUP), Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal.

Fernando Schmitt (F)

Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), Rua Júlio Amaral de Carvalho 45, 4200-135 Porto, Portugal.
Department of Pathology, Faculty of Medicine of the University of Porto (FMUP), Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal.
CINTESIS@RISE, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal.

Classifications MeSH